Skip to main content

Published locations for Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patients

User login

  • Reset your password
  • /content/evolocumab-second-pcsk9-inhibitor-approved-lower-ldl-high-risk-patients
  • /familypracticenews/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower
  • /internalmedicinenews/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower
  • /clinicalendocrinologynews/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved
  • /ecardiologynews/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower-ldl
  • /cardiology/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower-ldl-high
  • /endocrinology/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower-ldl
  • /internalmedicine/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower-ldl
  • /familymedicine/article/102287/lipid-disorders/evolocumab-second-pcsk9-inhibitor-approved-lower-ldl